非小细胞肺癌术后EGFR-TKIs辅助治疗研究现状与前景

Current Status and Prospect of Research on EGFR-TKIs after Non-Small Cell Lung Cancer Resection

基于多项循证医学证据等级较高的临床试验结果,2010年美国国家综合癌症网络指南将针对表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKIs)的靶向治疗列入一线治疗晚期非小细胞肺癌(NSCLC)患者的新选择,替代了传统化学治疗在晚期NSCLC一线治疗中的地位。然而,EGFR-TKIs能否在NSCLC术后辅助治疗中显示其独特优势,仍属未知。目前,关于EGFR-TKIs应用于NSCLC根治性手术切除后的辅助治疗领域的临床研究正在火热进行中。该文将NSCLC术后EGFR-TKIs辅助治疗研究现状与前景予以初步探讨。

Based on lots of clinical trials of high level of evidence-based medicine,EGFR-TKIs were recommended for first-line treatment of advanced non-small-cell lung cancer（ NSCLC） in NCCN guidelines,replacing the chemotherapy. However,it is still uncertain if EGFR-TKIs is effective for patients after surgery for NSCLC. Recently,more and more researches have been continuously developing in order to evaluate the effectiveness of EGFR-TKIs in NSCLC patients after surgery. Here is to make a preliminary discussion on current situation of EGFR-TKIs in treating NSCLC patients after resection.